| Literature DB >> 33092100 |
Zhigang Hu1, Junting Cao1, Guangyu Liu1, Huilin Zhang1, Xiaolin Liu1.
Abstract
In China, the production for duck meat is second only to that of chicken, and the demand for duck meat is also increasing. However, there is still unclear on the internal mechanism of regulating skeletal muscle growth and development in duck. This study aimed to identity candidate genes related to growth of duck skeletal muscle and explore the potential regulatory mechanism. RNA-seq technology was used to compare the transcriptome of skeletal muscles in black Muscovy ducks at different developmental stages (day 17, 21, 27, 31, and 34 of embryos and postnatal 6-month-olds). The SNPs and InDels of black Muscovy ducks at different growth stages were mainly in "INTRON", "SYNONYMOUS_CODING", "UTR_3_PRIME", and "DOWNSTREAM". The average number of AS in each sample was 37,267, mainly concentrated in TSS and TTS. Besides, a total of 19 to 5377 DEGs were detected in each pairwise comparison. Functional analysis showed that the DEGs were mainly involved in the processes of cell growth, muscle development, and cellular activities (junction, migration, assembly, differentiation, and proliferation). Many of DEGs were well known to be related to growth of skeletal muscle in black Muscovy duck, such as MyoG, FBXO1, MEF2A, and FoxN2. KEGG pathway analysis identified that the DEGs were significantly enriched in the pathways related to the focal adhesion, MAPK signaling pathway and regulation of the actin cytoskeleton. Some DEGs assigned to these pathways were potential candidate genes inducing the difference in muscle growth among the developmental stages, such as FAF1, RGS8, GRB10, SMYD3, and TNNI2. Our study identified several genes and pathways that may participate in the regulation of skeletal muscle growth in black Muscovy duck. These results should serve as an important resource revealing the molecular basis of muscle growth and development in duck.Entities:
Keywords: duck; gene expression; growth stage; skeletal muscle; transcriptome
Year: 2020 PMID: 33092100 PMCID: PMC7590229 DOI: 10.3390/genes11101228
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
qPCR primer sequences of black Muscovy duck.
| Groups | Primer Name | Primer Sequence (5′-3′) | Amplicon Size | Regulated |
|---|---|---|---|---|
| gCHD | F: TGCAGAAGCAATATTACAAGT | Male: 467 bp | ||
| R: AATTCATTATCATCTGGTGG | ||||
| BE17B_vs_BE21B | F:CCAAAACAGGAACACTTCGCA | 167 bp | Down | |
| R:AAAAGTCGCTCAGCCTGTTCT | ||||
|
| F:AAAGGGCTACCTGCACTTCC | 188 bp | Down | |
| R:CTGCACCCACCTTCAGCAT | ||||
| BE17B_vs_BE27B | F:AGATGGACCGCAACGAAT | 150 bp | Up | |
| R:CAGCAAGGACGGAGATGA | ||||
| F:CGCCAGTCCTCCTTTTCTGT | 175 bp | Down | ||
| R:ATTTCACGACGGATGGTGCT | ||||
| BE17B_vs_BE31B | F:GACGTACTTGGTCTGGGTCA | 158 bp | Up | |
| R:GCACCCCACCTTACAACCTC | ||||
| F:CCGCTCAGAAAGGAGGTGATT | 172 bp | Up | ||
| R:CTCCCTTTTCAGCCCATCACT | ||||
| BE17B_vs_BE34B |
| F:TTCCAGGACAAGGTTCCTGTT | 229 bp | Down |
| BE17B_vs_BM6B | F: TGTCTTTGCTTGGCGCTACT | 214 bp | Down | |
| F:TCGGATTAGTGATGCCCACC | 240 bp | Down | ||
| BE17L_vs_BE21L | F:CAAGCCACGACCAGAGAGAT | 176 bp | Up | |
| F:ACCCTGCTGTGCGTAAGA | 232 bp | Down | ||
| BE17L_vs_BE27L | F:TCTCCTATCCCGTGAGCCAA | 131 bp | Down | |
| BE17L_vs_BE31L | F:GGGAGTTTTCCTTGCCCCAG | 196 bp | Down | |
| F:AGGGGAAGGTCGGGAAAGTT | 201 bp | Down | ||
| BE17L_vs_BE34L | F:GTACAGCAGGTAGGTGTGGAA | 226 bp | Down | |
| BE17L_vs_BM6L | F:CATCGCAGTGATCGTGTTGA | 229 bp | Up | |
| F:GGCCACTGGTAATGACATGCT | 109 bp | Down | ||
| BE17B_vs_BE17L | F:GCGATTCTGTGTGGGAGACA | 106 bp | Up | |
| BE21B_vs_BE21L |
| F:GAGGCGGAGAAGAAGGTGATT | 147 bp | Up |
| F:CTGATGTGAACCTCCAGGGC | 218 bp | Down | ||
| BE27B_vs_BE27L |
| F:CGAAACCATCTGCTACCCCA | 213 bp | Up |
| F:TACAGCACCCAGACGACAAC | 114 bp | Down | ||
| BE31B_vs_BE31L | F:GTCTGTCCGGGTAGAGTCGT | 242 bp | Down | |
| BE34B_vs_BE34L | F:ACGAAAATGCCGTCTCTGGT | 172 bp | Up | |
| BM6B_vs_BM6L |
| F:GCAGGGAGCTGGAACTGAG | 148 bp | Up |
| F:AGCACTCCAGTTTCGGCTAC | 226 bp | Down | ||
|
| F: CCCTGTATGCCTCTGGTCG | 194 bp |
Note: BE17B: Breast muscle of black Muscovy duck on day 17 of the incubation period; BE17L: Leg muscle of black Muscovy duck on day 17 of the incubation period. The same below.
The feed composition of black Muscovy duck.
| Ingredient | Content (%) | Nutrient | Content (%) |
|---|---|---|---|
| Corn | 56.00 | Crude protein | 15.700 |
| Soybean meal | 23.80 | Calcium | 0.900 |
| Corn gluten meal | 10.00 | Total phosphorus | 0.680 |
| Limestone | 7.00 | Available phosphorus | 0.450 |
| CaHPO4 | 1.50 | Salt | 0.370 |
| Premix | 1.00 | Lysine | 0.760 |
| NaCl | 0.30 | Methionine | 0.387 |
| Lys·HCl | 0.30 | Methionine + Cystine | 0.654 |
| 0.10 | Isoleucine | 0.534 | |
| Total | 100.00 | Threonine | 0.579 |
| Tryptophan | 0.194 | ||
| Crude fiber | 4.100 | ||
| Crude fat | 3.400 | ||
| Crude ash | 5.200 | ||
| Avian metabolizable energy | 2875 Mcal·kg−1 |
RNA-Seq data from breast muscle and leg muscle of black Muscovy duck.
| Samples | Clean Reads | Clean Bases | GC Content | ≥Q30 (%) |
|---|---|---|---|---|
| BE17B1 | 26,764,472 | 7,980,103,934 | 50.51% | 93.57% |
| BE17B2 | 32,024,936 | 9,563,668,162 | 50.63% | 93.35% |
| BE17B3 | 23,594,320 | 7,046,658,352 | 50.99% | 92.86% |
| BE17L1 | 26,550,573 | 7,917,527,738 | 50.81% | 93.07% |
| BE17L2 | 33,105,790 | 9,881,964,696 | 51.01% | 92.80% |
| BE17L3 | 22,233,811 | 6,608,083,230 | 50.44% | 93.75% |
| BE21B1 | 21,356,816 | 6,372,442,332 | 50.93% | 93.10% |
| BE21B2 | 23,023,064 | 6,874,209,792 | 50.50% | 92.30% |
| BE21B3 | 22,232,157 | 6,643,515,660 | 50.10% | 91.93% |
| BE21L1 | 27,233,943 | 8,132,501,326 | 50.35% | 92.25% |
| BE21L2 | 23,821,161 | 7,114,195,066 | 50.77% | 92.71% |
| BE21L3 | 25,252,424 | 7,545,013,174 | 51.35% | 92.99% |
| BE27B1 | 26,005,019 | 7,766,530,628 | 51.05% | 92.74% |
| BE27B2 | 26,902,913 | 8,034,045,734 | 50.82% | 92.73% |
| BE27B3 | 24,226,391 | 7,227,540,800 | 51.53% | 92.75% |
| BE27L1 | 23,634,707 | 7,060,587,498 | 51.47% | 92.59% |
| BE27L2 | 25,561,499 | 7,630,071,354 | 51.34% | 93.31% |
| BE27L3 | 29,341,501 | 8,760,492,104 | 51.16% | 93.13% |
| BE31B1 | 21,708,384 | 6,481,320,616 | 50.43% | 93.32% |
| BE31B2 | 21,045,091 | 6,284,463,090 | 50.48% | 92.65% |
| BE31B3 | 23,666,137 | 7,071,687,724 | 50.01% | 93.80% |
| BE31L1 | 21,773,785 | 6,504,542,434 | 50.79% | 92.41% |
| BE31L2 | 19,700,766 | 5,883,221,398 | 50.94% | 92.35% |
| BE31L3 | 25,067,398 | 7,480,770,550 | 50.95% | 92.68% |
| BE34B1 | 19,970,569 | 5,959,632,696 | 51.20% | 91.89% |
| BE34B2 | 21,641,494 | 6,468,354,774 | 50.57% | 92.51% |
| BE34B3 | 24,247,593 | 7,240,167,310 | 50.04% | 91.36% |
| BE34L1 | 19,825,346 | 5,925,722,250 | 49.19% | 92.01% |
| BE34L2 | 20,622,571 | 6,154,061,186 | 50.82% | 91.72% |
| BE34L3 | 21,504,291 | 6,418,738,234 | 50.92% | 91.70% |
| BM6B1 | 27,888,927 | 8,312,322,988 | 52.05% | 93.09% |
| BM6B2 | 26,315,704 | 7,841,240,550 | 51.31% | 93.29% |
| BM6B3 | 32,141,926 | 9,592,590,862 | 52.51% | 92.91% |
| BM6L1 | 22,567,829 | 6,744,703,784 | 56.80% | 92.26% |
| BM6L2 | 25,330,860 | 7,561,056,178 | 53.01% | 92.95% |
| BM6L3 | 26,270,786 | 7,826,518,320 | 50.75% | 93.01% |
Single nucleotide polymorphism (SNP) statistics of each sample.
| Samples | SNP Number | Genic SNP | Intergenic SNP | Transition | Transversion | Heterozygosity |
|---|---|---|---|---|---|---|
| BE17B1 | 483,071 | 442,220 | 40,851 | 71.88% | 28.12% | 5.15% |
| BE17B2 | 533,462 | 479,697 | 53,765 | 71.91% | 28.09% | 5.18% |
| BE17B3 | 459,298 | 410,856 | 48,442 | 71.94% | 28.06% | 5.03% |
| BE17L1 | 444,914 | 405,784 | 39,130 | 72.19% | 27.81% | 5.32% |
| BE17L2 | 530,400 | 482,360 | 48,040 | 71.78% | 28.22% | 5.49% |
| BE17L3 | 458,580 | 416,890 | 41,690 | 72.03% | 27.97% | 5.09% |
| BE21B1 | 431,604 | 387,058 | 44,546 | 72.05% | 27.95% | 4.92% |
| BE21B2 | 468,195 | 420,675 | 47,520 | 71.82% | 28.18% | 4.96% |
| BE21B3 | 440,935 | 395,737 | 45,198 | 71.80% | 28.20% | 4.73% |
| BE21L1 | 437,821 | 400,429 | 37,392 | 72.14% | 27.86% | 5.25% |
| BE21L2 | 389,009 | 356,065 | 32,944 | 72.51% | 27.49% | 5.24% |
| BE21L3 | 347,547 | 315,990 | 31,557 | 72.68% | 27.32% | 5.79% |
| BE27B1 | 536,317 | 492,673 | 43,644 | 71.70% | 28.30% | 5.22% |
| BE27B2 | 634,028 | 574,484 | 59,544 | 71.12% | 28.88% | 4.74% |
| BE27B3 | 542,335 | 494,968 | 47,367 | 71.56% | 28.44% | 4.88% |
| BE27L1 | 406,931 | 374,739 | 32,192 | 72.26% | 27.74% | 4.27% |
| BE27L2 | 412,229 | 379,360 | 32,869 | 72.25% | 27.75% | 5.59% |
| BE27L3 | 446,540 | 410,485 | 36,055 | 71.98% | 28.02% | 5.50% |
| BE31B1 | 463,381 | 425,359 | 38,022 | 71.92% | 28.08% | 5.23% |
| BE31B2 | 475,408 | 426,377 | 49,031 | 71.77% | 28.23% | 5.28% |
| BE31B3 | 437,040 | 398,822 | 38,218 | 71.91% | 28.09% | 5.40% |
| BE31L1 | 293,728 | 264,407 | 29,321 | 72.66% | 27.34% | 5.07% |
| BE31L2 | 290,393 | 261,387 | 29,006 | 72.68% | 27.32% | 4.31% |
| BE31L3 | 356,589 | 317,875 | 38,714 | 72.17% | 27.83% | 5.23% |
| BE34B1 | 353,066 | 320,045 | 33,021 | 72.24% | 27.76% | 5.03% |
| BE34B2 | 66,777 | 60,706 | 6071 | 74.87% | 25.13% | 47.28% |
| BE34B3 | 466,221 | 416,752 | 49,469 | 71.79% | 28.21% | 4.87% |
| BE34L1 | 401,531 | 359,502 | 42,029 | 71.91% | 28.09% | 5.05% |
| BE34L2 | 347,704 | 312,392 | 35,312 | 72.09% | 27.91% | 5.00% |
| BE34L3 | 326,042 | 295,401 | 30,641 | 72.38% | 27.62% | 5.59% |
| BM6B1 | 76,822 | 69,735 | 7087 | 74.74% | 25.26% | 42.54% |
| BM6B2 | 76,472 | 70,083 | 6389 | 74.82% | 25.18% | 40.16% |
| BM6B3 | 114,505 | 104,733 | 9772 | 73.88% | 26.12% | 38.46% |
| BM6L1 | 23,381 | 20,572 | 2809 | 76.34% | 23.66% | 48.09% |
| BM6L2 | 66,117 | 60,659 | 5458 | 75.23% | 24.77% | 44.45% |
| BM6L3 | 85,270 | 77,902 | 7368 | 74.24% | 25.76% | 40.48% |
SNP Number: Total numbers of SNPs; Genic SNP: Total numbers of SNPs in the genic region; Intergenic SNP: Total numbers of SNPs between genes; Transition: The percentage that the transition-type SNP accounts for all SNP locis; Transversion: The percentage that the transversion-type SNP loci accounts for all SNP sites; Heterozygosity: The percentage that the heterozygous SNPs account for all SNPs.
Figure 1Annotation and classification of SNP/InDel. (a) The annotation result of SNP in breast muscle; (b) the annotation result of SNP in leg muscle; (c) the annotation result of InDel in breast muscle; (d) the annotation result of InDel in leg muscle.
Figure 2The predicted number of variable splices in black Muscovy ducks during different incubation stages. (a–f) represent the predicted number of variable splices in black Muscovy ducks on day 17, 21, 27, 31, and 34 of incubation and postnatal 6-month-old, respectively. Note: The horizontal axis represents number to one of alternative transcripts, the vertical axis represents types of alternative splicing events.
Statistical results of differentially expressed genes.
| DEGs | DEGnumber (newGene) | Up-Regulated (newGene) | Down-Regulated (newGene) |
|---|---|---|---|
| BE17B_vs_BE21B | 410 (24) | 218 (22) | 192 (2) |
| BE17B_vs_BE27B | 1958 (148) | 1162 (138) | 796 (10) |
| BE17B_vs_BE31B | 1517 (108) | 925 (101) | 592 (7) |
| BE17B_vs_BE34B | 1460 (79) | 852 (73) | 608 (6) |
| BE17B_vs_BM6B | 5377 (339) | 2580 (187) | 2797 (152) |
| BE17L_vs_BE21L | 655 (24) | 371 (16) | 284 (8) |
| BE17L_vs_BE27L | 2866 (185) | 1606 (148) | 1260 (37) |
| BE17L_vs_BE31L | 4413 (344) | 2440 (295) | 1973 (49) |
| BE17L_vs_BE34L | 4326 (342) | 2374 (299) | 1952 (43) |
| BE17L_vs_BM6L | 4560 (303) | 2303 (168) | 2257 (135) |
| BE17B_vs_BE17L | 214 (13) | 162 (6) | 52 (7) |
| BE21B_vs_BE21L | 1256 (194) | 523 (20) | 733 (174) |
| BE27B_vs_BE27L | 195 (27) | 51 (2) | 144 (25) |
| BE31B_vs_BE31L | 1226 (96) | 606 (63) | 620 (33) |
| BE34B_vs_BE34L | 19 (3) | 5 (1) | 14 (2) |
| BM6B_vs_BM6L | 104 (13) | 58 (6) | 46 (7) |
Figure 3GO enrichment analysis of differentially expressed genes (DEGs) in breast muscle. (a) BE17B_vs_BE21B; (b) BE17B_vs_BE27B. Note: The abscissa were GO terms, the ordinate on the left was percentage of genes in all genes annotated with GO, right was the number of gene. The same below.
Figure 4GO enrichment analysis of DEGs in breast muscle (a) BE17B_vs_BE31B; (b) BE17B_vs_BE34B.
Figure 5GO enrichment analysis of DEGs in breast muscle of BE17B_vs_BM6B.
Figure 6GO enrichment analysis of DEGs in leg muscle. (a) BE17L_vs_BE21L; (b) BE17L_vs_BE27L.
Figure 7GO enrichment analysis of DEGs in leg muscle. (a) BE17L_vs_BE31L; (b) BE17L_vs_BE34L.
Figure 8GO enrichment analysis of DEGs in leg muscle of BE17L_vs_BM6L.
Figure 9GO enrichment analysis of DEGs in the comparison of breast and leg muscle. (a) BE17B_vs_BE17L; (b) BE21B_vs_BE21L.
Figure 10GO enrichment analysis of DEGs in the comparison of breast and leg muscle. (a) BE27B_vs_BE27L; (b) BE31B_vs_BE31L.
Figure 11GO enrichment analysis of DEGs in the comparison of breast and leg muscle. (a) BE34B_vs_BE34L; (b) BM6B_vs_BM6L.
The most enriched GO terms.
| DEGs | The Most Enriched GO Terms | ||||
|---|---|---|---|---|---|
| BE17B_vs_BE21B | regulation of calcium ion import | regulation of muscle filament sliding speed | regulation of euchromatin binding | dorsal root ganglion development | negative regulation of fibroblast growth factor receptor signaling pathway |
| BE17B_vs_BE27B | actin binding | motor activity | positive regulation of myoblast proliferation | cell division | positive regulation of cell proliferation |
| BE17B_vs_BE31B | striated muscle contraction | regulation of muscle filament sliding | skeletal muscle fiber development | muscle contraction | positive regulation of myoblast differentiation |
| BE17B_vs_BE34B | chordate embryonic development | regulation of cell cycle | positive regulation of fibroblast proliferation | muscle contraction | positive regulation of substrate-dependent cell migration |
| BE17B_vs_BM6B | translation | immune response | regulation of cell size | regulation of cell growth | regulation of G2/M transition mitotic cell cycle |
| BE17L_vs_BE21L | cell proliferation | muscle contraction | skeletal muscle fiber development | skeletal muscle tissus development | regulation of muscle filament sliding |
| BE17L_vs_BE27L | egulation of transcription involved in cell fate commitment | calcium-mediated signaling | glucose transport | signal transduction | Wnt signaling pathway, calcium modulating pathway |
| BE17L_vs_BE31L | cell maturation | embryonic limb morphogenesis | muscle contraction | chordate embryonic development | immune response |
| BE17L_vs_BE34L | embryonic hindlimb morphogenesis | positive regulation of protein process | regulation of actin cytoskeleton organization | positive regulation of cell proliferation | L-glutamate transmembrane transport |
| BE17L_vs_BM6L | Wnt receptor catabolic process | embryonic hindlimb morphogenesis | glucose transport | protein folding | immune response |
| BE17B_vs_BE17L | myoblast migration involved in skeletal muscle regeneration | positive regulation of glucocorticoid receptor signaling pathways | regulation of multicellular organism growth | cell adhesion | skeletal system development |
| BE21B_vs_BE21L | positive regulation of cellular process | metabolic process | fibroblast migration | RNA-dependent DNA biosynthetic process | positive regulation of cellular process |
| BE27B_vs_BE27L | positive regulation of MHC class I biosynthetic process | immune response | metabotic process | ubiquitin-dependent protein catabolic process | transmembrane transport |
| BE31B_vs_BE31L | regulation of cell shape | embryonic organ development | translation | muscle structure morphogenesis | DNA-dependent DNA replication |
| BE34B_vs_BE34L | skeletal muscle cell differentiation | skeletal muscle fiber adaptation | myotube differentiation involved in skeletal muscle regeneration | positive regulation of skeletal muscle tissue regeneration | protein phosphorylation |
| BM6B_vs_BM6L | muscle structure development | regulation of biological quality | myoblast fate commitment | embryonic skeletal joint morphogenesis | negative regulation of skeletal muscle tissue development |
Figure 12KEGG annotation of DEGs in breast muscle. (a) BE17B_vs_BE21B; (b) BE17B_vs_BE27B. Note: In the figure, each circle represented a KEGG pathway, name of which was shown on the left legend. Abscissa was enrichment factors, showing the proportion of (a) to (b), (a) was the ration of differentially expressed genes in the pathway with all DEGs in all pathways, (b) was the ration of genes in the pathway with all genes in all pathways. The bigger the Rich factor is, the more significant the pathway is. The color of circle represented q value which is adjusted p value by multiple hypothesis testing. Thus, the smaller the q value is, the more significant the pathway is; the circle size represented the number of differentially expressed genes annotated with the pathway, the bigger circle size is, the higher number of genes is. The same below.
Figure 13KEGG annotation of DEGs in breast muscle. (a) BE17B_vs_BE31B; (b) BE17B_vs_BE34B.
Figure 14KEGG annotation of DEGs in breast muscle of BE17B_vs_BM6B.
Figure 15KEGG annotation of DEGs in leg muscle. (a) BE17L_vs_BE21L; (b) BE17L_vs_BE27L.
Figure 16KEGG annotation of DEGs in leg muscle. (a) BE17L_vs_BE31L; (b) BE17L_vs_BE34L.
Figure 17KEGG annotation of DEGs in leg muscle of BE17L_vs_BM6L.
Figure 18KEGG annotation of DEGs in the comparison of breast and leg muscle. (a) BE17B_vs_BE17L; (b) BE21B_vs_BE21L.
Figure 19KEGG annotation of DEGs in the comparison of breast and leg muscle. (a) BE27B_vs_BE27L; (b) BE31B_vs_BE31L.
Figure 20KEGG annotation of DEGs in the comparison of breast and leg muscle. (a) BE34B_vs_BE34L; (b) BM6B_vs_BM6L.
Top 5 of KEGG enrichment.
| DEGs | KEGG Enrichment | ||||
|---|---|---|---|---|---|
| BE17B_vs_BE21B | Focal adhesion | Regulation of actin cytoskeleton | MAPK signaling pathway | Wnt signaling pathway | ECM–receptor interaction |
| BE17B_vs_BE27B | Focal adhesion | Neuroactive ligand-receptor interaction | Purine metabolism | MAPK signaling pathway | Calcium signaling pathway |
| BE17B_vs_BE31B | Focal adhesion | MAPK signaling pathway | Purine metabolism | Cell cycle | Calcium signaling pathway |
| BE17B_vs_BE34B | Focal adhesion | MAPK signaling pathway | Neuroactive ligand–receptor interaction | Regulation of actin cytoskeleton | Endocytosis |
| BE17B_vs_BM6B | Leukocyte transendothelial migration | Thiamine metabolism | ErbB signaling pathway | Glucagon signaling pathway | RIG–I–like receptor signaling pathway |
| BE17L_vs_BE21L | Focal adhesion | Neuroactive ligand–receptor interaction | ECM–receptor interaction | MAPK signaling pathway | Regulation of actin cytoskeleton |
| BE17L_vs_BE27L | Neuroactive ligand–receptor interaction | Focal adhesion, | Calcium signaling pathway | MAPK signaling pathway | Oxidative phosphorylation |
| BE17L_vs_BE31L | Ribosome | Focal adhesion | Oxidative phosphorylation | MAPK signaling pathway | Regulation of actin cytoskeleton |
| BE17L_vs_BE34L | Focal adhesion | Neuroactive ligand–receptor interaction | Regulation of actin cytoskeleton | Oxidative phosphorylation | MAPK signaling pathway |
| BE17L_vs_BM6L | Neuroactive ligand–receptor interaction | MAPK signaling pathway | Oxidative phosphorylation | Focal adhesion | Calcium signaling pathway |
| BE17B_vs_BE17L | Focal adhesion | Neuroactive ligand–receptor interaction | ECM-receptor interaction | Cytokine–cytokine receptor interaction | Phagosome |
| BE21B_vs_BE21L | Focal adhesion | ECM–receptor interaction | Regulation of actin cytoskeleton | Phagosome | Neuroactive ligand–receptor interaction |
| BE27B_vs_BE27L | Glycerophospholipid metabolism | Glycerolipid metabolism | Tight junction | Cell adhesion molecules (CAMs) | Biosynthesis of amino acids |
| BE31B_vs_BE31L | Oxidative phosphorylation | Ribosome | Regulation of actin cytoskeleton | Calcium signaling pathway | MAPK signaling pathway |
| BE34B_vs_BE34L | Cell cycle | Endocytosis | MAPK signaling pathway | Cytokine–cytokine receptor interaction | Ubiquitin mediated proteolysis |
| BM6B_vs_BM6L | Adrenergic signaling in cardiomyocytes | Tight junction | Cardiac muscle contraction | MAPK signaling pathway | Apoptosis |
Figure 21qPCR verification of DEGs. “*” was considered significant difference (p < 0.05); “**” was considered extremely significant difference (p > 0.01).